Celator(R) Pharmaceuticals to Present at 10th Annual BIO CEO and Investor ...( PRINCETON N.J. Feb. 5 /- Celator ...)

PRINCETON, N.J., Feb. 5 /PRNewswire/ -- Celator Pharmaceuticals today announced that Andrew Janoff, Ph.D., chief executive officer, is scheduled to present on the company's business operations and clinical development programs at the 10th Annual Biotechnology Industry Organization (BIO) CEO and Investor Conference on Tuesday, February 12, 2008 at 9:30am ET at the Waldorf-Astoria in New York City.

About Celator

Celator Pharmaceuticals, Inc., is a privately held pharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex(TM), the company's drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies based on identifying a fixed, synergistic ratio of the drugs pre-clinically, incorporating that ratio in a drug delivery vehicle and maintaining the ratio in patients. The company pipeline includes: CPX-1 (a liposomal formulation of irinotecan: floxuridine), currently in a Phase 2 trial in patients with colorectal cancer; CPX-351 (a liposomal formulation of cytarabine: daunroubicin), currently in a Phase 1 trial in patients with leukemia; CPX 571 (a liposomal formulation of irinotecan: cisplatin), now positioned to advance to Phase 1; and multiple early stage pre-clinical development programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at http://www.celatorpharma.com.